‘Focus on getting Ranbaxy’s units USFDA nod one at a time’

Sun Pharma will focus on one plant at a time as it looks to make four manufacturing units of Ranbaxy, which have been banned by the US health regulator from exporting drugs to the US, compliant with laid out norms.

The Mumbai-based drug major, which acquired Ranbaxy in a $4 billion deal, feels it is important for the merged entity to "re- establish" the trust between Ranbaxy and the US Food and Drug Administration (USFDA).

"Clearly, we will focus our energies on one plant with a view to bring it back to compliance rather then focusing on all the plants in which the whole process would get significantly delayed," Sun Pharma managing director Dilip Shanghvi said in an analyst call.